Diagnostic Criteria and the Role of Free Testosterone in Male Hypogonadism

Definition and Diagnostic Thresholds

• The Endocrine Society (2010, 2018) strongly recommends diagnosing hypogonadism only when total testosterone is unequivocally low (< 300 ng/dL) on two separate early‑morning measurements and the patient has consistent hypogonadal symptoms【1】【2】.
• Total testosterone < 300 ng/dL must be confirmed in the same laboratory using a validated fasting morning assay (draw before 10 AM)【1】【2】.

When to Measure Free Testosterone (Second‑Line Testing)

• Free testosterone should be measured only in the following situations (Endocrine Society 2018):
  
  • Conditions that alter SHBG –
    
    • Low SHBG (e.g., obesity, type 2 diabetes, nephrotic syndrome, hypothyroidism, glucocorticoid or androgenic‑steroid use)【2】.
    • High SHBG (e.g., aging, HIV infection, cirrhosis, hyperthyroidism, anticonvulsant or estrogen use)【2】.
  • Borderline total testosterone (200–400 ng/dL) – specificity is limited (≈ 73.7 % at < 280 ng/dL); free testosterone helps clarify true androgen exposure【2】.

Clinical Algorithm for Confirming Hypogonadism

• Step 1 – Biochemical confirmation: obtain two early‑morning fasting total testosterone measurements; if both < 300 ng/dL, proceed to symptom assessment【1】【2】.
• Step 2 – Borderline values: if total testosterone is 200–400 ng/dL, measure free testosterone with a validated assay (equilibrium dialysis or calculated using accurate SHBG)【1】【2】.
• Step 3 – Symptom assessment: evaluate for sexual symptoms (reduced libido, erectile dysfunction, decreased morning erections), physical symptoms (fatigue, loss of muscle mass/strength, central adiposity, loss of body hair, gynecomastia), and psychological symptoms (depression, impaired concentration) – these are the domains most responsive to testosterone therapy【1】【2】.

Contraindications and Baseline Safety Testing

• Absolute contraindications (Endocrine Society 2010, 2018):
  
  • Known prostate or breast cancer【1】.
  • Hematocrit > 50 % (relative; many patients exceed 54 % on therapy)【2】.
  • Severe untreated obstructive sleep apnea【1】.
  • Severe lower urinary tract symptoms (IPSS > 19)【1】【2】.
  • Uncontrolled heart failure【1】.
• Baseline testing before initiating therapy (Endocrine Society 2018):
  
  • Hematocrit or hemoglobin.
  • PSA and digital rectal examination in men ≥ 40 y; PSA > 0.6 ng/mL at age 43 warrants urology referral【2】.

Excluding Reversible Causes Prior to Therapy

• Screen for and address obesity, type 2 diabetes, obstructive sleep apnea, chronic opioid use, chronic glucocorticoid use, and pituitary/hypothalamic disease (e.g., abnormal LH, FSH, prolactin) – these factors can cause functional hypogonadism that may improve with treatment of the underlying condition【2】.

Common Pitfalls and Evidence‑Based Solutions

• Pitfall 1 – Single low testosterone measurement: up to 30 % of men with an initial low value have a normal result on repeat testing【2】. Solution: always confirm with a second early‑morning measurement【1】【2】.
• Pitfall 2 – Treating without confirmed biochemical hypogonadism: free testosterone is a second‑line test intended only to clarify borderline total testosterone or SHBG abnormalities【1】【2】. Solution: adhere to the algorithm above and do not initiate therapy based solely on a normal total testosterone with low free testosterone.
• Pitfall 3 – Ignoring reversible causes in younger men: functional hypogonadism (e.g., obesity, opioids, systemic illness) is often reversible【2】. Solution: prioritize treatment of underlying conditions before considering testosterone therapy【2】.
• Pitfall 4 – Inadequate monitoring: testosterone and hematocrit should be re‑checked 3–6 months after initiation and annually thereafter; discontinue therapy if hematocrit exceeds 54 %【2】.

Guideline Consensus Summary

• The Endocrine Society (2010, 2018) and the American Urological Association (2018) define hypogonadism as total testosterone < 300 ng/dL on two separate early‑morning measurements plus compatible symptoms【1】【2】.
• Free testosterone is designated a second‑line test for cases of borderline total testosterone or suspected SHBG abnormalities【1】【2】.

All facts are derived from cited Endocrine Society and American Urological Association guidelines (references 1 and 2).

Guidelines for Diagnosis and Management of Adult Male Hypogonadism

Diagnosis

• The American Urological Association (AUA) strongly recommends confirming low testosterone with two separate early‑morning (before 10 AM) fasting total testosterone measurements performed in the same laboratory; both values must be < 300 ng/dL to establish the diagnosis【3】【4】【5】.
• Testosterone concentrations exhibit a diurnal pattern and are highest in the early morning, making timing of the draw essential for accurate assessment【3】【4】【5】.

Symptom Assessment

• Diagnosis requires both biochemical deficiency and clinically relevant symptoms; low testosterone alone is insufficient to justify therapy【3】【4】【5】【6】.
• Sexual symptoms to evaluate include reduced libido, erectile dysfunction, and decreased frequency of morning erections【5】【6】【7】.
• Physical symptoms include fatigue/low energy, loss of muscle mass or strength, increased central adiposity, loss of body hair, and gynecomastia【5】【6】【8】.
• Psychological symptoms to screen for are depression or mood changes, impaired concentration or memory, and reduced motivation【5】【8】.
• Physical examination should assess testicular size/consistency, body‑mass index and waist circumference, presence of gynecomastia, and androgen‑dependent body‑hair distribution【6】.
• Validated questionnaires are not recommended for determining eligibility for testosterone therapy【3】【5】.

Evaluation of Underlying (Reversible) Causes

• Prior to therapy, screen for secondary causes such as type 2 diabetes, obstructive sleep apnea, chronic opioid use, chronic corticosteroid use, and pituitary dysfunction【3】【5】【9】.

Baseline Testing Before Initiating Therapy

• Obtain a baseline hematocrit or hemoglobin; a hematocrit > 50 % is a relative contraindication to starting testosterone【10】【11】【9】.
• Perform PSA measurement and digital rectal examination; at age 43, a PSA > 0.6 ng/mL warrants further evaluation before therapy【10】【11】.
• Assess prostate‑cancer risk factors as part of the baseline work‑up【10】【11】.

Treatment Selection

• After confirming low testosterone and relevant symptoms, discuss the uncertain long‑term safety of testosterone therapy with the patient【7】【12】【13】.
• Intramuscular testosterone (enanthate or cypionate) is preferred as first‑line because it offers significantly lower cost with comparable efficacy and safety to transdermal preparations【13】.
• Transdermal gels are an acceptable alternative for patients who prefer daily application【10】【11】.

Monitoring Protocol

Initial Follow‑up (3–6 months)

• Re‑evaluate symptom response; discontinue therapy if no clinical improvement【13】.
• Measure serum testosterone and adjust the dose to achieve a mid‑normal range (≈ 400–700 ng/dL)【10】【11】.
• Check hematocrit; pause therapy if hematocrit > 54 % until it falls, then resume at a lower dose【10】【11】.
• Repeat PSA and digital rectal examination to monitor prostate health【10】【11】.

Ongoing Annual Monitoring

• Perform annual symptom assessment, hematocrit measurement, PSA with digital rectal examination, and serum testosterone testing to maintain levels within the mid‑normal range【10】【11】.

Urological Referral Triggers

• Refer if PSA rises > 1.4 ng/mL within any 12‑month period, PSA velocity exceeds 0.4 ng/mL per year after six months of therapy, or digital rectal examination is abnormal【10】【11】.

Clinical Pitfalls

• Initiating therapy after a single testosterone measurement without confirmation is the most common error; up to 25 % of treated men do not meet diagnostic criteria【3】【4】【5】.
• Treating asymptomatic men with borderline low testosterone is discouraged; the American College of Physicians recommends against testosterone therapy for improving energy, vitality, physical function, or cognition in men with age‑related low testosterone【13】.
• Monitoring failure is frequent—nearly 50 % of men on therapy lack follow‑up testosterone measurements, underscoring the necessity of regular monitoring to ensure therapeutic levels and detect adverse effects【3】【4】【10】【11】.
• In men ≤ 45 years old, secondary causes (e.g., obesity, medications, pituitary disease) are more likely than age‑related decline; thorough investigation is essential before attributing low testosterone to aging【3】.

Management and Monitoring of Testosterone Replacement Therapy in Patients with Low SHBG

Laboratory Monitoring and Safety

• Concurrent hematocrit measurement is essential at each testosterone assessment because polycythemia can exacerbate symptoms and mandates immediate dose reduction; therapy should be stopped if hematocrit exceeds 54 % – Endocrine Society recommendation (clinical guideline) 14.
• Hematocrit should be re‑checked at 3–6 months after any dose change and then annually to detect delayed polycythemia in patients requiring higher total‑testosterone doses (low SHBG) 14.
• Prostate‑specific antigen (PSA) and digital rectal examination are required at 3–6 months and annually in men ≥ 40 years; discontinue or refer if PSA rises >1.4 ng/mL within 12 months – Endocrine Society guidance 14.

Dosing Strategies for Low‑SHBG Patients

• Switch from bi‑weekly to weekly intramuscular testosterone injections (e.g., 100 mg weekly instead of 200 mg every 2 weeks) to reduce peak‑trough fluctuations that are amplified when SHBG is low – Endocrine Practice (American College of Endocrinology & American Association of Clinical Endocrinologists) recommendation 15.
• If weekly dosing does not achieve stable free testosterone, increase to twice‑weekly injections (e.g., 50–75 mg every 3.5 days) for more constant serum levels – same guideline 15.
• Avoid infrequent dosing of short‑acting esters (every‑2‑week schedule) because it creates wide swings in free testosterone that are poorly tolerated in the absence of SHBG buffering – Endocrine Practice cautionary note 15.

Addressing Comorbidities that Suppress SHBG

• Screen all low‑SHBG TRT patients for obstructive sleep apnea, as untreated OSA independently lowers testosterone and SHBG; treatment can improve hormonal status – clinical evidence from the Journal of Clinical Endocrinology & Metabolism 14.

Criteria for Therapy Continuation or Discontinuation

• If free testosterone reaches the target range (≥ 70 pg/mL) but the patient remains symptomatic after 6–12 months, evaluate non‑androgenic causes such as depression, sleep disorders, or chronic illness – Endocrine Society and Annals of Internal Medicine guidance [14][16].
• Discontinue testosterone therapy if, after 12 months of optimized dosing with confirmed therapeutic free testosterone levels, there is no meaningful clinical improvement – consensus from the Journal of Clinical Endocrinology & Metabolism and Annals of Internal Medicine [14][16].

Additional Safety Monitoring Specific to Low‑SHBG Patients

• Perform cardiovascular risk assessment before initiating or re‑initiating TRT; the Endocrine Society advises deferring therapy for 3–6 months after major cardiovascular events, recognizing low SHBG itself as a cardiovascular risk marker – guideline statement 14.

Guidelines for Testosterone Therapy When Serum Testosterone Is Normal but DHT Is Low

Diagnostic Requirements for Initiating Testosterone Therapy

• The Endocrine Society states that testosterone replacement therapy should only be started when both (1) two separate early‑morning fasting total testosterone measurements are < 300 ng/dL and (2) the patient has compatible clinical symptoms; normal testosterone (≥ 300 ng/dL) excludes hypogonadism regardless of DHT level. Strong guideline recommendation. 17

Recommendations Against Initiating DHT or Testosterone Therapy in This Scenario

• The American College of Physicians recommends against prescribing testosterone therapy for improving energy, vitality, or sexual function in men whose serum testosterone is within the normal range, because TRT provides little‑to‑no benefit in this population. Moderate‑quality evidence. 17
• The Endocrine Society and American Urological Association define hypogonadism requiring testosterone < 300 ng/dL on two measurements plus symptoms; therefore, isolated low DHT with normal testosterone does not meet criteria for androgen therapy. Guideline recommendation. 17

Regulatory and Therapeutic Status of DHT Preparations

• No FDA‑approved DHT formulation exists for the treatment of male hypogonadism in the United States. Regulatory status. [18][19]20
• Historical transdermal DHT patches were developed only to augment DHT levels in men already receiving testosterone therapy, not to treat isolated low DHT. Historical context. [18][19]20
• DHT cannot be aromatized to estradiol; using DHT as monotherapy may adversely affect bone density, lipid metabolism, and cardiovascular health, and its role as a standalone treatment remains investigational and unsupported by current clinical guidelines. Guideline stance. 18

Evidence Summary on TRT Effectiveness in Men Without Biochemical Hypogonadism

• A systematic review by the American College of Physicians (2020) found that testosterone therapy has little‑to‑no effect on physical functioning, depressive symptoms, energy levels, or cognition in men who do not have organic hypogonadism (i.e., normal testosterone). Moderate‑quality evidence. 17